Captrust Financial Advisors Sells 19,255 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Captrust Financial Advisors reduced its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 15.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 103,740 shares of the biotechnology company's stock after selling 19,255 shares during the period. Captrust Financial Advisors owned 0.10% of Corcept Therapeutics worth $4,801,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Capital Performance Advisors LLP bought a new position in shares of Corcept Therapeutics during the third quarter valued at about $25,000. Kathleen S. Wright Associates Inc. purchased a new stake in Corcept Therapeutics during the third quarter worth about $36,000. Blue Trust Inc. increased its holdings in Corcept Therapeutics by 125.4% during the second quarter. Blue Trust Inc. now owns 3,526 shares of the biotechnology company's stock worth $115,000 after buying an additional 1,962 shares during the last quarter. GAMMA Investing LLC increased its holdings in Corcept Therapeutics by 85.4% during the third quarter. GAMMA Investing LLC now owns 2,490 shares of the biotechnology company's stock worth $115,000 after buying an additional 1,147 shares during the last quarter. Finally, nVerses Capital LLC increased its holdings in Corcept Therapeutics by 62.5% during the second quarter. nVerses Capital LLC now owns 3,900 shares of the biotechnology company's stock worth $127,000 after buying an additional 1,500 shares during the last quarter. 93.61% of the stock is owned by institutional investors.

Corcept Therapeutics Price Performance

Shares of CORT stock traded up $1.18 during trading hours on Wednesday, reaching $60.85. The stock had a trading volume of 743,075 shares, compared to its average volume of 1,166,250. The stock's fifty day simple moving average is $50.82 and its 200 day simple moving average is $39.61. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. Corcept Therapeutics Incorporated has a 12 month low of $20.84 and a 12 month high of $62.22. The firm has a market capitalization of $6.38 billion, a PE ratio of 47.36 and a beta of 0.51.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.14. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The company had revenue of $182.55 million during the quarter, compared to analyst estimates of $171.97 million. During the same period last year, the business earned $0.28 earnings per share. Corcept Therapeutics's revenue was up 47.7% compared to the same quarter last year. On average, equities research analysts predict that Corcept Therapeutics Incorporated will post 1.35 EPS for the current year.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, insider William Guyer sold 6,606 shares of the business's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $48.97, for a total value of $323,495.82. Following the completion of the sale, the insider now directly owns 5,796 shares of the company's stock, valued at $283,830.12. The trade was a 53.27 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Gary Charles Robb sold 11,000 shares of the firm's stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $46.28, for a total value of $509,080.00. Following the transaction, the insider now directly owns 22,772 shares in the company, valued at $1,053,888.16. This trade represents a 32.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,611 shares of company stock worth $1,210,548 over the last three months. 20.50% of the stock is owned by insiders.

Analysts Set New Price Targets

CORT has been the subject of several recent research reports. Piper Sandler lifted their target price on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 18th. Truist Financial lifted their target price on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the stock a "buy" rating in a research note on Monday, September 30th. Sandler O'Neill reiterated a "buy" rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Corcept Therapeutics in a research note on Thursday, October 31st. Finally, StockNews.com downgraded shares of Corcept Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Monday, November 25th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $65.25.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.